Opus Genetics (NASDAQ:IRD) Receives “Buy” Rating from HC Wainwright

Opus Genetics (NASDAQ:IRD)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $8.00 target price on the stock.

Opus Genetics Stock Performance

Shares of NASDAQ IRD opened at $1.11 on Wednesday. The firm has a market cap of $34.88 million, a price-to-earnings ratio of -1.01 and a beta of 0.16. The firm’s 50-day moving average is $1.15. Opus Genetics has a 52 week low of $0.81 and a 52 week high of $2.65.

Insider Activity at Opus Genetics

In other Opus Genetics news, CEO George Magrath bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The stock was purchased at an average price of $0.98 per share, for a total transaction of $98,000.00. Following the purchase, the chief executive officer now directly owns 599,150 shares in the company, valued at $587,167. This trade represents a 20.03 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.60% of the stock is owned by corporate insiders.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.